Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Downsview, Canada Clinical Trials

A listing of Downsview, Canada clinical trials actively recruiting patients volunteers.

RESULTS

Found (9) clinical trials

Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

This is a randomized, multi-center, double-blind, parallel-group study, enrolling approximately 100 male subjects diagnosed with CP/CPPS to evaluate the effect of 12-week treatment with AQX-1125 (active drug) compared to placebo. The subjects will be randomized to receive orally once-daily either AQX-1125 (200 mg) or placebo in a 1:1 ratio across ...

Phase

2.2 miles

Learn More »

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent ( 12 years) patients with uncontrolled asthma with respect to change from baseline in forced expiratory volume in 1 second ...

Phase

4.96 miles

Learn More »

Lactoferrin Infant Feeding Trial - LIFT_Canada

Almost 3,000 very low birth weight (VLBW), <1500g preterm infants are born and treated in Canada annually. About 1,200 either die or survive with severe brain or lung injury, retinopathy, late-onset sepsis or necrotizing enterocolitis (NEC), each of which is associated with substantial risk of childhood disability. Lactoferrin is an ...

Phase

5.87 miles

Learn More »

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants taking "dummy" medicine. In addition to taking the medicine, participants will ...

Phase

5.87 miles

Learn More »

Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

Aminosalicylate (5-ASA) agents have proven effective for inducing and maintaining remission in mild to moderate ulcerative colitis (UC) and thus are commonly used as first-line agents for patients with Crohn's disease (CD) in remission. However, there is uncertainty regarding their effectiveness for CD. In this open-label, randomized study, participants with ...

Phase

7.25 miles

Learn More »

A 3D Analysis of Mandibular Plating Strategies in Oromandibular Reconstruction.

Patients will be identified through attendance at the Wharton Head and Neck Clinic at Princess Margaret Hospital or attendance at the Toronto General Hospital Otolaryngology - Head & Neck Surgery clinic as requiring resection of mandibular pathology and subsequent reconstruction with bony free flap. Chart review (electronic) of these patients ...

Phase N/A

7.26 miles

Learn More »

Rolandic Epilepsy Genomewide Association International Study

Epilepsy is a common neurological disorder affecting 1% of the population. There are over 30 types of epilepsy, some common, some rare. Most epilepsies arise in childhood and have a genetic cause. Approximately 25% of child patients have "Rolandic Epilepsy" or RE, also known as Benign Epilepsy with Centrotemporal Spikes ...

Phase N/A

7.48 miles

Learn More »

Strategies To OPpose SUGARS With Non-nutritive Sweeteners Or Water (STOP SUGARS NOW) Trial

BACKGROUND AND SIGNIFICANCE: International health agencies and chronic disease associations have called for reductions in free/added sugars to 5-10% of energy to address the growing epidemics of obesity and diabetes. Attention has focused especially on the reduction of the major source of free sugars, sugar sweetened beverages (SSBs), the excess ...

Phase N/A

8.02 miles

Learn More »

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

This is study is a placebo controlled study where subjects with moderate to severe atopic dermatitis will be randomized (1:1:1:1) to receive ASN002 at 40 mg, 60 mg, or 80 mg, or placebo once daily for 12 weeks. Eligible subjects will get the opportunity to enroll in the 24 month ...

Phase

8.76 miles

Learn More »